文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-SSA PET/CT在神经内分泌肿瘤患者管理及肽受体放射性核素治疗反应预测中的作用:系统综述与Meta分析

The Role of 68 Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors : A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2022-04-29

该系统综述与Meta分析评估68Ga-DOTA-SSA PET/CT对神经内分泌肿瘤患者治疗决策的影响及对PRRT反应的预测能力,纳入39项研究,其中24项研究2266例患者进入Meta分析,显示PET/CT使36%的患者临床管理发生改变,部分研究报告治疗前较高SUV及基于PET的影像组学特征与PRRT反应相关。

要点

  • 68Ga-DOTA-SSA PET/CT使36%(95%CI 31%-41%)的神经内分泌肿瘤患者临床管理发生改变。
  • 15项研究618例患者评估其对PRRT的预测能力,8项研究认为治疗前较高SUV有利于PRRT。
  • 4项研究认为基于PET的影像组学特征可预测生长抑素受体异质性及PRRT反应。

核心结论

  • 68Ga-DOTA-SSA PET/CT除诊断能力外,可影响神经内分泌肿瘤患者的治疗决策,并可能预测PRRT反应。
  • 作者认为应开展更稳健的研究以更好阐明生长抑素受体PET/CT在优化治疗以改善临床结局中的预后作用。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Scopus截至2021年12月的文献。
  • 纳入标准为≥10例确诊或疑似神经内分泌肿瘤且治疗前接受68Ga-DOTA-SSA PET/CT分期检查的患者。
  • 共纳入39项研究,其中24项研究2266例患者进入Meta分析。
  • 采用随机效应模型进行Meta分析,总结与PRRT结局相关的PET/CT衍生参数。

主要发现

  • 68Ga-DOTA-SSA PET/CT使36%(95%CI 31%-41%;范围3%-66%)的患者临床管理发生改变。
  • 15项研究618例患者评估了68Ga-DOTA-SSA PET/CT对PRRT的预后预测能力。
  • 8项研究认为治疗前较高SUV有利于PRRT。
  • 4项研究认为基于PET的生长抑素受体异质性影像组学特征可预测PRRT反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为应开展更稳健的研究以更好阐明生长抑素受体PET/CT在优化治疗以改善临床结局中的预后作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to identify and evaluate the role of 68 Ga-DOTA-somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response. PATIENTS AND METHODS: A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging 68 Ga-DOTA-SSA PET/CT. A meta-analysis using the random-effects model was conducted to determine the overall change in management after PET/CT, whereas PET/CT-derived parameters that correlated with PRRT outcome were summarized from studies that assessed its predictive capabilities. RESULTS: A total of 39 studies were included in this systemic review, of which 2266 patients from 24 studies were included for meta-analysis. We showed that PET/CT resulted in a change in clinical management in 36% (95% confidence interval, 31%-41%; range, 3%-66%) of patients. Fifteen studies consisting of 618 patients examined the prognostic ability of 68 Ga-DOTA-SSA PET/CT for PRRT. Of those, 8 studies identified a higher pretreatment SUV to favor PRRT, and 4 identified PET-based radiomic features for somatostatin receptor heterogeneity to be predictive of PRRT response. CONCLUSIONS: Along with its diagnostic abilities, 68 Ga-DOTA-SSA PET/CT can impact treatment decision-making and may predict PRRT response in patients with NETs. More robust studies should be conducted to better elucidate the prognostic role of somatostatin receptor PET/CT in optimizing treatment for clinical outcome.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lee ONY, Tan KV, Tripathi V, et al. The Role of 68 Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors : A Systematic Review and Meta-analysis. Clin Nucl Med. 2022. PMID: 35485851. doi:10.1097/RLU.0000000000004235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。